Epizyme Inc. (NASDAQ:EPZM) dropped 2.1% during mid-day trading on Monday . The company traded as low as $7.13 and last traded at $7.16, with a volume of 314,600 shares traded. The stock had previously closed at $7.31.

EPZM has been the topic of a number of recent analyst reports. Wedbush reissued an “outperform” rating and issued a $22.00 price target on shares of Epizyme in a report on Monday, May 9th. Mizuho lowered their price target on shares of Epizyme from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, May 10th. HC Wainwright reissued a “buy” rating on shares of Epizyme in a report on Tuesday, May 10th. Zacks Investment Research downgraded shares of Epizyme from a “buy” rating to a “hold” rating in a report on Wednesday, May 11th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $26.00 price target on shares of Epizyme in a report on Monday, June 20th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Epizyme currently has a consensus rating of “Buy” and a consensus price target of $23.11.

The firm’s market cap is $414.96 million. The company’s 50-day moving average price is $9.03 and its 200 day moving average price is $10.31.

Epizyme (NASDAQ:EPZM) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.03. On average, equities analysts predict that Epizyme Inc. will post ($2.19) EPS for the current fiscal year.

In other Epizyme news, insider Robert A. Copeland sold 4,000 shares of the business’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $10.37, for a total transaction of $41,480.00. Following the completion of the sale, the insider now directly owns 35,538 shares in the company, valued at approximately $368,529.06. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.